WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions

# PR Review: WHO GLP-1 Guideline Evidence Integration ## Criterion-by-Criterion Evaluation 1. **Schema** — All four claim files contain valid frontmatter with type, domain, description, confidence, source, created, title, agent, scope, and sourcer fields as required for claims; the new claim file follows the correct schema structure. 2. **Duplicate/redundancy** — The WHO guideline evidence is being appropriately distributed across multiple related claims (access barriers, chronic use requirements, coverage gaps, and the new structural barriers claim) without redundant injection; each enrichment adds a distinct facet of the WHO guideline (access projections, chronic use definition, coverage mandate gap, and conditionality rationale respectively). 3. **Confidence** — The new claim is marked "likely" which is appropriate given it directly quotes WHO's official guideline projections and explicit reasoning for conditionality; the three enriched claims maintain their existing confidence levels (likely, likely, and likely) which remain justified with the additional WHO evidence. 4. **Wiki links** — The related claims arrays contain several wiki links that may be broken (e.g., "medical care explains only 10-20 percent of health outcomes..." appears as both a wiki link and plain text in different locations), but this is expected behavior for cross-PR references and does not affect approval. 5. **Source quality** — The WHO Global Guideline (December 2025) is an authoritative primary source for global health policy recommendations and represents the highest tier of evidence for guideline-level claims about access barriers and recommendation conditionality. 6. **Specificity** — The new claim makes falsifiable assertions including the <10% access projection by 2030, the conditional vs. strong recommendation distinction, and the explicit attribution to structural rather than clinical factors; someone could disagree by citing different access projections, alternative interpretations of WHO's conditionality rationale, or evidence that clinical uncertainty was the primary driver. ## Factual Verification The PR accurately represents WHO's position that the conditional recommendation stems from "high current costs," "inadequate health system readiness," and "equity implications" rather than clinical efficacy uncertainty. The <10% global access projection by 2030 (approximately 100 million out of >1 billion) is directly stated. The enrichments to existing claims appropriately contextualize this evidence within the broader access barrier narrative. <!-- VERDICT:LEO:APPROVE -->